Nctid:
NCT00000197
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D019970", "term"=>"Cocaine-Related Disorders"}], "ancestors"=>[{"id"=>"D019966", "term"=>"Substance-Related Disorders"}, {"id"=>"D064419", "term"=>"Chemically-Induced Disorders"}, {"id"=>"D001523", "term"=>"Mental Disorders"}], "browseLeaves"=>[{"id"=>"M19100", "name"=>"Behavior, Addictive", "relevance"=>"LOW"}, {"id"=>"M21841", "name"=>"Cocaine-Related Disorders", "asFound"=>"Cocaine-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M21837", "name"=>"Substance-Related Disorders", "relevance"=>"LOW"}, {"id"=>"M30302", "name"=>"Chemically-Induced Disorders", "relevance"=>"LOW"}, {"id"=>"M14473", "name"=>"Psychotic Disorders", "relevance"=>"LOW"}, {"id"=>"M4815", "name"=>"Mental Disorders", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Behaviors and Mental Disorders", "abbrev"=>"BXM"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Substance Related Disorders", "abbrev"=>"BC25"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D011433", "term"=>"Propranolol"}], "ancestors"=>[{"id"=>"D000319", "term"=>"Adrenergic beta-Antagonists"}, {"id"=>"D018674", "term"=>"Adrenergic Antagonists"}, {"id"=>"D018663", "term"=>"Adrenergic Agents"}, {"id"=>"D018377", "term"=>"Neurotransmitter Agents"}, {"id"=>"D045504", "term"=>"Molecular Mechanisms of Pharmacological Action"}, {"id"=>"D045505", "term"=>"Physiological Effects of Drugs"}, {"id"=>"D000889", "term"=>"Anti-Arrhythmia Agents"}, {"id"=>"D000959", "term"=>"Antihypertensive Agents"}, {"id"=>"D014665", "term"=>"Vasodilator Agents"}], "browseLeaves"=>[{"id"=>"M14298", "name"=>"Propranolol", "asFound"=>"2 years", "relevance"=>"HIGH"}, {"id"=>"M6271", "name"=>"Cocaine", "relevance"=>"LOW"}, {"id"=>"M3671", "name"=>"Adrenergic beta-Antagonists", "relevance"=>"LOW"}, {"id"=>"M20746", "name"=>"Adrenergic Agents", "relevance"=>"LOW"}, {"id"=>"M20755", "name"=>"Adrenergic Antagonists", "relevance"=>"LOW"}, {"id"=>"M20504", "name"=>"Neurotransmitter Agents", "relevance"=>"LOW"}, {"id"=>"M4213", "name"=>"Anti-Arrhythmia Agents", "relevance"=>"LOW"}, {"id"=>"M4277", "name"=>"Antihypertensive Agents", "relevance"=>"LOW"}, {"id"=>"M17412", "name"=>"Vasodilator Agents", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Anti-Arrhythmia Agents", "abbrev"=>"AnArAg"}, {"name"=>"Antihypertensive Agents", "abbrev"=>"AnAg"}, {"name"=>"Vasodilator Agents", "abbrev"=>"VaDiAg"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Vasoconstrictor Agents", "abbrev"=>"VaCoAg"}, {"name"=>"Central Nervous System Depressants", "abbrev"=>"CNSDep"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE2"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"primaryPurpose"=>"TREATMENT"}, "enrollmentInfo"=>{"count"=>0}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1987-01"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2016-10", "completionDateStruct"=>{"date"=>"2002-01", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2017-01-11", "studyFirstSubmitDate"=>"1999-09-20", "studyFirstSubmitQcDate"=>"1999-09-20", "lastUpdatePostDateStruct"=>{"date"=>"2017-01-12", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"1999-09-21", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"2002-01", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Side effects"}, {"measure"=>"Cocaine use"}, {"measure"=>"Cocaine withdrawal"}, {"measure"=>"Cocaine craving"}, {"measure"=>"Mood and anxiety"}, {"measure"=>"Clinical improvement"}]}, "oversightModule"=>{"oversightHasDmc"=>false}, "conditionsModule"=>{"keywords"=>["cocaine"], "conditions"=>["Cocaine-Related Disorders"]}, "descriptionModule"=>{"briefSummary"=>"The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT"], "maximumAge"=>"49 years", "minimumAge"=>"25 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Please contact site for information."}, "identificationModule"=>{"nctId"=>"NCT00000197", "briefTitle"=>"Propranolol for Treatment of Cocaine Addiction - 2", "organization"=>{"class"=>"NIH", "fullName"=>"National Institute on Drug Abuse (NIDA)"}, "officialTitle"=>"Propranolol for Treatment of Cocaine Addiction", "orgStudyIdInfo"=>{"id"=>"NIDA-00238-2"}, "secondaryIdInfos"=>[{"id"=>"K20DA000238", "link"=>"https://reporter.nih.gov/quickSearch/K20DA000238", "type"=>"NIH"}]}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"Propranolol", "type"=>"DRUG"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"19104 6178", "city"=>"Philadelphia", "state"=>"Pennsylvania", "country"=>"United States", "facility"=>"University of Pennsylvania", "geoPoint"=>{"lat"=>39.95233, "lon"=>-75.16379}}], "overallOfficials"=>[{"name"=>"Kyle Kampman, M.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"University of Pennsylvania"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"National Institute on Drug Abuse (NIDA)", "class"=>"NIH"}, "collaborators"=>[{"name"=>"University of Pennsylvania", "class"=>"OTHER"}], "responsibleParty"=>{"oldNameTitle"=>"Kyle Kampman", "oldOrganization"=>"University of Pennsylvania"}}}}
